$2.95
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Sunshine Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Lauderdale, Florida and currently employs 50 full-time employees. The company went IPO on 2008-08-15. Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Country

US

CEO

Dr. Steve Slilaty

IPO date

2008

Employees

50

ISIN

US8677818820

Key stats

Open

$3.11

Volume

501.56K

Market cap

$2.25M

Prev. close

$3.11

Impl / hst vl

-

Open interest

$0.00

$2.95

Day’s Range

$3.12

$0.13

52W Range

$3.34

Valuation

61
Valuation score
Undervalued
P/E
-
P/S
0.06
P/B
0.08
Current ratio
5.46
Debt / Equity
-0.50
ROE
-24.23%
Gross margin
26.20%
Income growth
25.74%
FCF growth
-57.59

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$57.12
The top 3 analysts forecasts that 12-month price may increase by 1,836.27%, with a low of $56.56 and a high of $58.80
$56.56
Low
$57.12
Avg
$58.80
High
Current price

Earnings

Q2 ‘26 revenue
$9.26M
Q2 ‘26 net income
-$1.56M
Revenue
Net income
Previous EPS
-
Estimate EPS
-$0.17
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply